E-cigarette effectiveness in smoking cessation

Nov.21.2022
E-cigarette effectiveness in smoking cessation
A study by the UK Cochrane Group found that nicotine e-cigarettes can improve smoking cessation rates.

Recently, the UK-based Cochrane Collaboration conducted 78 studies involving 22,052 smokers, comparing the use of electronic cigarettes with the following factors:


Nicotine replacement therapy (such as patches or gum);


Varenicline, a medication that helps people quit smoking;


Nicotine-free electronic cigarette;


Other types of electronic cigarettes that contain nicotine (such as pods);


Actions of support, such as advice or consultation.


The research was mostly conducted in the United States (34 studies), United Kingdom (16 studies), and Italy (8 studies).


Key Conclusion


Using nicotine-containing e-cigarettes is more effective than using nicotine replacement therapy or non-nicotine e-cigarettes for quitting smoking. The most common adverse effects of using e-cigarettes with nicotine are throat or oral irritation, headaches, coughing and nausea. As people continue to use nicotine e-cigarettes, these effects become lessened over time.


Research summary


There is strong evidence to suggest that nicotine-containing e-cigarettes are more effective for smoking cessation than NRT, while moderate quality evidence suggests that nicotine-containing e-cigarettes are more effective for smoking cessation than non-nicotine e-cigarettes. Comparing nicotine replacement therapy to standard care or no treatment also shows benefit, but with lower certainty and requiring further research to confirm the effect. In most cases, the confidence intervals for data on AEs, SAEs, and other safety indicators are broad, with no differences observed between nicotine and non-nicotine e-cigarettes in terms of AEs, or between nicotine e-cigarettes and NRT. The overall incidence rate of SAEs was low across all study groups. No evidence was found for serious harm from nicotine e-cigarettes, but the longest follow-up period was two years and the number of studies was limited. The primary limitation of the evidence base continues to be imprecision due to limited numbers of RCTs and typically low event rates, but further RCTs are currently ongoing. To ensure that this review continues to provide up-to-date information for decision-makers, it is a living system review. Searches are conducted monthly and the review is updated when new relevant evidence becomes available. Please refer to the Cochrane Systematic Reviews Database for the current status of this review.


Statement:


This article is based on third-party information that has been edited by machine translation, and is only intended for industry communication and learning purposes.


This article does not represent the views of 2FIRSTS and 2FIRSTS cannot confirm the truthfulness or accuracy of the article's content. The translation of this article is only for the purpose of industry-related communication and research.


Due to limitations in the translator's abilities, the translated article may not fully express the original content. Please refer to the original article for accuracy.


2FIRSTS maintains complete alignment with the Chinese government in regards to any domestic, Hong Kong, Macau, Taiwan, or international statements and positions.


The copyright of the compiled information belongs to the original media and author. If there is any infringement, please contact us to have it removed.


This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

UK reminds vaping firms to apply for new excise duty registration from April 2026
UK reminds vaping firms to apply for new excise duty registration from April 2026
HMRC has issued a reminder urging vaping manufacturers, importers and warehouse operators to prepare for registration under the UK’s new Vaping Products Duty, with applications opening in April 2026 and the duty taking effect in October.
Feb.10
Product | “Prefilled + Refill” Combo, Up to 30,000 Puffs Claimed: DOJO BLAST 30K PRO Launches in the UK and France
Product | “Prefilled + Refill” Combo, Up to 30,000 Puffs Claimed: DOJO BLAST 30K PRO Launches in the UK and France
DOJO has launched the upgraded BLAST 30K PRO on its official website. The device features a (2+8) ml ×2 “2 ml prefilled pod + 8 ml refill” configuration, delivering 20 ml of e-liquid per kit and claiming up to 30,000 puffs. It is also labeled as fully compatible with BLAST 10K Pods.
Jan.12 by 2FIRSTS.ai
South Dakota Senate Committee Advances Bill Tightening Nicotine Retail Rules
South Dakota Senate Committee Advances Bill Tightening Nicotine Retail Rules
South Dakota Senate Bill 221 (SB 221), which seeks to regulate the retail sale of nicotine products, has passed the Senate Health and Human Services Committee with a unanimous 7–0 recommendation. The bill was significantly amended, expanding from three to nine pages and shifting its focus from vapor products alone to all nicotine products.
Regulations
Feb.22
China Business Journal Reports: Multiple New E-Cigarette Policies Enter Public Consultation Phase in China, Covering Capacity Control and Credit Management
China Business Journal Reports: Multiple New E-Cigarette Policies Enter Public Consultation Phase in China, Covering Capacity Control and Credit Management
China Business Journal, citing a review of policy documents released by the State Tobacco Monopoly Administration in early 2026, said China’s latest e-cigarette rules target credit-based regulation, capacity controls and national standards revisions.Alan Zhao, co-founder of 2Firsts, said tighter oversight will speed consolidation, curb noncompliance and reduce destructive competition.
Jan.12 by 2FIRSTS.ai
Virginia appeals to the Fourth Circuit over partial block on flavored vape ban enforcement
Virginia appeals to the Fourth Circuit over partial block on flavored vape ban enforcement
Virginia has asked the Fourth Circuit to overturn a district court order that partially blocked enforcement of the commonwealth’s flavored vape ban. In a notice, the state told U.S. District Judge David J. Novak it seeks to upend his December ruling that Virginia’s Chapter 23.2 statute is preempted by the Food, Drug and Cosmetic Act and the Family Smoking Prevention and Tobacco Control Act.
Jan.12 by 2FIRSTS.ai
Rosstandart: packaging and design requirements for vapes to be tightened in early 2026
Rosstandart: packaging and design requirements for vapes to be tightened in early 2026
Rosstandart head Anton Shalaev told TASS that Russia will tighten requirements for the packaging and design of vapes and other electronic nicotine delivery systems in early 2026.
Jan.12 by 2FIRSTS.ai